Down-Regulation of β-Catenin by Activated p53

REFERENCES

• Abarzua, P., J. E. LoSardo, M. L. Gubler, and A. Neri. 1995. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res. 55:3490–3494.
   PubMed Web of Science ®Google Scholar
• Adams, C., and W. Nelson. 1998. Cytomechanics of cadherin-mediated cell-cell adhesion. Curr. Opin. Cell Biol. 10:572–577.
   PubMedGoogle Scholar
• Albrechtsen, N., I. Dornreiter, F. Grosse, E. Kim, L. Wiesmuller, and W. Deppert. 1999. Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene 18:7706–7717.
   PubMed Web of Science ®Google Scholar
• Ashcroft, M., Y. Taya, and K. H. Vousden. 2000. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. 20:3224–3233.
   PubMed Web of Science ®Google Scholar
• Ashcroft, M., and K. H. Vousden. 1999. Regulation of p53 stability. Oncogene 18:7637–7643.
   PubMed Web of Science ®Google Scholar
• Avantaggiati, M. L., V. Ogryzko, K. Gardner, A. Giordano, A. S. Levine, and K. Kelly. 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89:1175–1184.
   PubMed Web of Science ®Google Scholar
• Baker, S. J., E. R. Fearon, J. M. Nigro, S. R. Hamilton, A. C. Preisinger, J. M. Jessup, P. vanTuinen, D. H. Ledbetter, D. F. Barker, Y. Nakamura, R. White, and B. Vogelstein. 1989. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217–221.
   PubMed Web of Science ®Google Scholar
• Banks, L., G. Matlashewski, and L. Crawford. 1986. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem. 159:529–534.
   PubMedGoogle Scholar
• Behrens, J., J. von Kries, M. Kuhl, L. Bruhn, D. Wedlich, R. Grosschedl, and W. Birchmeier. 1996. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382:638–642.
   PubMed Web of Science ®Google Scholar
• Ben-Ze'ev, A., and B. Geiger. 1998. Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer. Curr. Opin. Cell Biol. 10:629–639.
   PubMed Web of Science ®Google Scholar
• Brancolini, C., D. Lazarevic, J. Rodriguez, and C. Schneider. 1997. Dismantling cell-cell contacts during apoptosis is coupled to a caspase-dependent proteolytic cleavage of beta-catenin. J. Cell. Biol. 139:759–771.
   PubMed Web of Science ®Google Scholar
• Burns, T. F., and W. S. El-Deiry. 1999. The p53 pathway and apoptosis. J. Cell. Physiol. 181:231–239.
   PubMed Web of Science ®Google Scholar
• Chan, E., U. Gat, J. McNiff, and E. Fuchs. 1999. A common human skin tumour is caused by activating mutations in beta-catenin. Nat. Genet. 21:410–413.
   PubMed Web of Science ®Google Scholar
• Crawford, H., B. Fingleton, L. Rudolph-Owen, K. Goss, B. Rubinfeld, P. Polakis, and L. Matrisian. 1999. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18:2883–2891.
   PubMed Web of Science ®Google Scholar
• Damalas, A., A. Ben-Ze'ev, I. Simcha, M. Shtutman, J. Leal, J. Zhurinsky, B. Geiger, and M. Oren. 1999. Excess β-catenin promotes accumulation of transcriptionally active p53. EMBO J. 18:3054–3063.
   PubMed Web of Science ®Google Scholar
• de La Coste, A., B. Romagnolo, P. Billuart, C. A. Renard, M. A. Buendia, O. Soubrane, M. Fabre, J. Chelly, C. Beldjord, A. Kahn, and C. Perret. 1998. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA 95:8847–8851.
   PubMed Web of Science ®Google Scholar
• Delattre, O., S. Olschwang, D. J. Law, T. Melot, Y. Remvikos, R. J. Salmon, X. Sastre, P. Validire, A. P. Feinberg, and G. Thomas. 1989. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 2:353–356.
   PubMedGoogle Scholar
• el-Deiry, W. S.. 1998. Regulation of p53 downstream genes. Semin. Cancer Biol. 8:345–357.
   PubMed Web of Science ®Google Scholar
• el-Deiry, W. S., J. W. Harper, P. M. O'Connor, V. E. Velculescu, C. E. Canman, J. Jackman, J. A. Pietenpol, M. Burrell, D. E. Hill, Y. Wang, et al.. 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1169–1174.
   PubMed Web of Science ®Google Scholar
• Eliyahu, D., D. Michalovitz, S. Eliyahu, O. Pinhasi-Kimhi, and M. Oren. 1989. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA 86:8763–8767.
   PubMed Web of Science ®Google Scholar
• Fuchs, S. Y., A. Chen, Y. Xiong, Z. Q. Pan, and Z. Ronai. 1999. HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin. Oncogene 18:2039–2046.
   PubMedGoogle Scholar
• Fukuchi, T., M. Sakamoto, H. Tsuda, K. Maruyama, S. Nozawa, and S. Hirohashi. 1998. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 58:3526–3528.
   PubMed Web of Science ®Google Scholar
• Gamallo, C., J. Palacios, G. Moreno, J. Calvo de Mora, A. Suarez, and A. Armas. 1999. Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am. J. Pathol. 155:527–536.
   PubMedGoogle Scholar
• Garcia-Rostan, G., G. Tallini, A. Herrero, T. G. D'Aquila, M. L. Carcangiu, and D. L. Rimm. 1999. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 59:1811–1815.
   PubMed Web of Science ®Google Scholar
• Gat, U., R. DasGupta, L. Degenstein, and E. Fuchs. 1998. De novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell 95:605–614.
   PubMed Web of Science ®Google Scholar
• Gradl, D., M. Kuhl, and D. Wedlich. 1999. The Wnt/Wg signal transducer beta-catenin controls fibronectin expression. Mol. Cell. Biol. 19:5576–5587.
   PubMed Web of Science ®Google Scholar
• Harada, N., Y. Tamai, T. Ishikawa, B. Sauer, K. Takaku, M. Oshima, and M. M. Taketo. 1999. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 18:5931–5942.
   PubMed Web of Science ®Google Scholar
• Harlow, E. D., L. V. Crawford, D. C. Pim, and N. M. Williamson. 1981. Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol. 39:861–869.
   PubMed Web of Science ®Google Scholar
• Hart, M., J. Concordet, I. Lassot, I. Albert, R. del los Santos, H. Durand, C. Perret, B. Rubinfeld, F. Margottin, R. Benarous, and P. Polakis. 1999. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr. Biol. 9:207–210.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., Y. Barak, and M. Oren. 1996. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15:1596–1606.
   PubMed Web of Science ®Google Scholar
• He, T., T. Chan, B. Vogelstein, and K. Kinzler. 1999. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335–345.
   PubMed Web of Science ®Google Scholar
• He, T., A. Sparks, C. Rago, H. Hermeking, L. Zawel, L. da Costa, P. Morin, B. Vogelstein, and K. Kinzler. 1998. Identification of c-MYC as a target of the APC pathway. Science 281:1509–1512.
   PubMed Web of Science ®Google Scholar
• Hecht, A., K. Vleminckx, M. Stemmler, F. van Roy, and R. Kemler. 2000. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J. 19:1839–1850.
   PubMed Web of Science ®Google Scholar
• Huber, O., R. Korn, J. McLaughlin, M. Ohsugi, B. Herrmann, and R. Kemler. 1996. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech. Dev. 59:3–10.
   PubMed Web of Science ®Google Scholar
• Janus, F., N. Albrechtsen, I. Dornreiter, L. Wiesmuller, F. Grosse, and W. Deppert. 1999. The dual role model for p53 in maintaining genomic integrity. Cell. Mol. Life Sci. 55:12–27.
   PubMed Web of Science ®Google Scholar
• Jeng, Y. M., M. Z. Wu, T. L. Mao, M. H. Chang, and H. C. Hsu. 2000. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett. 152:45–51.
   PubMedGoogle Scholar
• Kam, Z., M. Jones, O. H. Chen, D. Agad, and J. W. Sedat. 1993. Design and construction of an optimal illumination system for quantitative wide-field multi-dimensional microscopy. Bioimaging 1:71–81.
   Google Scholar
• Kikuchi, A.. 2000. Regulation of beta-catenin signaling in the Wnt pathway. Biochem. Biophys. Res. Commun. 268:243–248.
   PubMed Web of Science ®Google Scholar
• Kikuchi-Yanoshita, R., M. Konishi, S. Ito, M. Seki, K. Tanaka, Y. Maeda, H. Iino, M. Fukayama, M. T. Koike. Mori, et al.. 1992. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res. 52:3965–3971.
   PubMed Web of Science ®Google Scholar
• Kinzler, K. W., and B. Vogelstein. 1996. Lessons from hereditary colorectal cancer. Cell 87:159–170.
   PubMed Web of Science ®Google Scholar
• Kitagawa, M., S. Hatakeyama, M. Shirane, M. Matsumoto, N. Ishida, K. Hattori, I. Nakamichi, A. Kikuchi, K. Nakayama, and K. Nakayama. 1999. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J. 18:2401–2410.
   PubMed Web of Science ®Google Scholar
• Koch, A., D. Denkhaus, S. Albrecht, I. Leuschner, D. von Schweinitz, and T. Pietsch. 1999. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res. 59:269–273.
   PubMed Web of Science ®Google Scholar
• Koesters, R., R. Ridder, A. Kopp-Schneider, D. Betts, V. Adams, F. Niggli, J. Briner, and M. von Knebel Doeberitz. 1999. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res. 59:3880–3882.
   PubMed Web of Science ®Google Scholar
• Laurent-Puig, P., H. Blons, and P. H. Cugnenc. 1999. Sequence of molecular genetic events in colorectal tumorigenesis. Eur. J. Cancer Prev. 9 (Suppl. 1):S39–S47.
   Google Scholar
• Levine, A. J.. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323–331.
   PubMed Web of Science ®Google Scholar
• Liu, C., Y. Kato, Z. Zhang, V. Do, B. Yankner, and X. He. 1999. Beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc. Natl. Acad. Sci. USA 96:6273–6278.
   PubMed Web of Science ®Google Scholar
• Liu, J., J. Stevens, C. Rote, H. Yost, Y. Hu, K. Neufeld, R. White, and N. Matsunami. 2001. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol. Cell 7:927–936.
   PubMed Web of Science ®Google Scholar
• Mann, B., M. Gelos, A. Siedow, M. Hanski, A. Gratchev, M. Ilyas, W. Bodmer, M. Moyer, E. Riecken, and H. Buhr. 1999. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. USA 96:1603–1608.
   PubMed Web of Science ®Google Scholar
• Mao, B., W. Wu, Y. Li, D. Hoppe, P. Stannek, A. Glinka, and C. Niehrs. 2001. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411:321–325.
   PubMed Web of Science ®Google Scholar
• Marin, M. C., C. A. Jost, M. S. Irwin, J. A. DeCaprio, D. Caput, and W. G. Kaelin Jr.. 1998. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol. Cell. Biol. 18:6316–6324.
   PubMedGoogle Scholar
• Matsuzawa, S.-I., and J. Reed. 2001. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol. Cell 7:915–926.
   PubMed Web of Science ®Google Scholar
• Mirabelli-Primdahl, L., R. Gryfe, H. Kim, A. Millar, C. Luceri, D. Dale, E. Holowaty, B. Bapat, S. Gallinger, and M. Redston. 1999. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res. 59:3346–3351.
   PubMed Web of Science ®Google Scholar
• Miyagishi, M., R. Fujii, M. Hatta, E. Yoshida, N. Araya, A. Nagafuchi, S. Ishihara, T. Nakajima, and A. Fukamizu. 2000. Regulation of lef-mediated transcription and p53-dependent pathway by associating beta-catenin with CBP/p300. J. Biol. Chem. 275:35170–35175.
   PubMedGoogle Scholar
• Miyoshi, Y., K. Iwao, G. Nawa, H. Yoshikawa, T. Ochi, and Y. Nakamura. 1998. Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol. Res. 10:591–594.
   PubMedGoogle Scholar
• Miyoshi, Y., H. Nagase, H. Ando, A. Horii, S. Ichii, S. Nakatsuru, T. Aoki, Y. Miki, T. Mori, and Y. Nakamura. 1992. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum. Mol. Genet. 1:229–233.
   PubMedGoogle Scholar
• Molenaar, M., M. van de Wetering, M. Oosterwegel, J. Peterson-Maduro, S. Godsave, V. Korinek, J. Roose, O. Destree, and H. Clevers. 1996. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 86:391–399.
   PubMed Web of Science ®Google Scholar
• Morin, P., A. Sparks, V. Korinek, N. Barker, H. Clevers, B. Vogelstein, and K. Kinzler. 1997. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787–1790.
   PubMed Web of Science ®Google Scholar
• Munemitsu, S., I. Albert, B. Souza, B. Rubinfeld, and P. Polakis. 1995. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc. Natl. Acad. Sci. USA 92:3046–3050.
   PubMed Web of Science ®Google Scholar
• Narayan, S., and A. S. Jaiswal. 1997. Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N′-nitro-N-nitrosoguanidine requires p53. J. Biol. Chem. 272:30619–30622.
   PubMedGoogle Scholar
• Nigro, J. M., S. J. Baker, A. C. Preisinger, J. M. Jessup, R. Hostetter, K. Cleary, S. H. Bigner, N. Davidson, S. Baylin, P. Devilee, T. Glover, F. S. Collins, A. Weston, R. Modali, C. C. Harris, and B. Vogelstein. 1989. Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705–708.
   PubMed Web of Science ®Google Scholar
• Oren, M.. 1999. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274:36031–36034.
   PubMed Web of Science ®Google Scholar
• Orford, K., C. Orford, and S. Byers. 1999. Exogenous expression of beta-catenin regulates contact inhibition, anchorage independent growth, anoikis, and radiation-induced cell cycle arrest. J. Cell Biol. 146:855–867.
   PubMed Web of Science ®Google Scholar
• Oshima, M., H. Oshima, K. Kitagawa, M. Kobayashi, C. Itakura, and M. Taketo. 1995. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc. Natl. Acad. Sci. USA 92:4482–4486.
   PubMed Web of Science ®Google Scholar
• Peifer, M.. 1997. Beta-catenin as oncogene: the smoking gun. Science 275:1752–1753.
   PubMed Web of Science ®Google Scholar
• Polakis, P.. 1999. The oncogenic activation of beta-catenin. Curr. Opin. Genet. Dev. 9:15–21.
   PubMed Web of Science ®Google Scholar
• Polakis, P.. 2000. Wnt signaling and cancer. Genes Dev. 14:1837–1851.
   PubMed Web of Science ®Google Scholar
• Renard, C. A., G. Fourel, M. P. Bralet, C. Degott, A. De La Coste, C. Perret, P. Tiollais, and M. A. Buendia. 2000. Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: oncogenic mutations of beta-catenin and synergistic effect of p53 null alleles. Oncogene 19:2678–2686.
   PubMedGoogle Scholar
• Roose, J., and H. Clevers. 1999. TCF transcription factors: molecular switches in carcinogenesis. Biochim. Biophys. Acta 1424:M23–M37.
   PubMedGoogle Scholar
• Roperch, J. P., V. Alvaro, S. Prieur, M. Tuynder, M. Nemani, F. Lethrosne, L. Piouffre, M. C. Gendron, D. Israeli, J. Dausset, M. Oren, R. Amson, and A. Telerman. 1998. Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. Nat. Med. 4:835–838.
   PubMed Web of Science ®Google Scholar
• Rubinfeld, B., P. Robbins, M. El-Gamil, I. Albert, E. Porfiri, and P. Polakis. 1997. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790–1792.
   PubMed Web of Science ®Google Scholar
• Sadot, E., I. Simcha, K. Iwai, A. Ciechanover, B. Geiger, and A. Ben-Ze'ev. 2000. Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system. Oncogene 19:1992–2001.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J., and J. D. Weber. 2000. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10:94–99.
   PubMed Web of Science ®Google Scholar
• Shtutman, M., J. Zhurinsky, I. Simcha, C. Albanese, M. D'Amico, R. Pestell, and A. Ben-Ze'ev. 1999. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 96:5522–5527.
   PubMed Web of Science ®Google Scholar
• Simcha, I., M. Shtutman, D. Salomon, J. Zhurinsky, E. Sadot, B. Geiger, and A. Ben-Ze'ev. 1998. Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin. J. Cell Biol. 141:1433–1448.
   PubMed Web of Science ®Google Scholar
• Simms, L. A., G. Radford-Smith, K. G. Biden, R. Buttenshaw, M. Cummings, J. R. Jass, J. Young, S. J. Meltzer, and B. A. Leggett. 1998. Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers. Oncogene 17:2003–2008.
   PubMedGoogle Scholar
• Sionov, R. V., and Y. Haupt. 1999. The cellular response to p53: the decision between life and death. Oncogene 18:6145–6157.
   PubMed Web of Science ®Google Scholar
• Sparks, A., P. Morin, B. Vogelstein, and K. Kinzler. 1998. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58:1130–1134.
   PubMed Web of Science ®Google Scholar
• Subler, M. A., D. W. Martin, and S. Deb. 1992. Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66:4757–4762.
   PubMedGoogle Scholar
• Takemaru, K., and R. Moon. 2000. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J. Cell Biol. 149:249–254.
   PubMed Web of Science ®Google Scholar
• Tetsu, O., and F. McCormick. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422–426.
   PubMed Web of Science ®Google Scholar
• Van de Craen, M., G. Berx, I. Van den Brande, W. Fiers, W. Declercq, and P. Vandenabeele. 1999. Proteolytic cleavage of beta-catenin by caspases: an in vitro analysis. FEBS Lett. 458:167–170.
   PubMedGoogle Scholar
• van de Wetering, M., R. Cavallo, D. Dooijes, M. van Beest, J. van Es, J. Loureiro, A. Ypma, D. Hursh, T. Jones, A. Bejsovec, M. Peifer, M. Mortin, and H. Clevers. 1997. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 88:789–799.
   PubMed Web of Science ®Google Scholar
• Voeller, H., C. Truica, and E. Gelmann. 1998. Beta-catenin mutations in human prostate cancer. Cancer Res. 58:2520–2523.
   PubMed Web of Science ®Google Scholar
• Vojtesek, B., J. Bartek, C. A. Midgley, and D. P. Lane. 1992. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods 151:237–244.
   PubMed Web of Science ®Google Scholar
• Wang, J., J. Shou, and X. Chen. 2000. Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene 19:1843–1848.
   PubMedGoogle Scholar
• Webster, G. A., and N. D. Perkins. 1999. Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol. 19:3485–3495.
   PubMed Web of Science ®Google Scholar
• Wei, Y., M. Fabre, S. Branchereau, F. Gauthier, G. Perilongo, and M. A. Buendia. 2000. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 19:498–504.
   PubMed Web of Science ®Google Scholar
• Winston, J., P. Strack, P. Beer-Romero, C. Chu, S. Elledge, and J. Harper. 1999. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 13:270–283.
   PubMed Web of Science ®Google Scholar
• Wright, K., P. Wilson, S. Morland, I. Campbell, M. Walsh, T. Hurst, B. Ward, M. Cummings, and G. Chenevix-Trench. 1999. Beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int. J. Cancer 82:625–629.
   PubMedGoogle Scholar
• Xu, L., R. B. Corcoran, J. W. Welsh, D. Pennica, and A. J. Levine. 2000. WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev. 14:585–595.
   PubMed Web of Science ®Google Scholar
• Yost, C., M. Torres, J. Miller, E. Huang, D. Kimelman, and R. Moon. 1996. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10:1443–1454.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., H. Hartmann, V. Do, D. Abramowski, C. Sturchler-Pierrat, M. Staufenbiel, B. Sommer, M. van de Wetering, H. Clevers, P. Saftig, B. De Strooper, X. He, and B. Yankner. 1998. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395:698–702.
   PubMed Web of Science ®Google Scholar
• Zhurinsky, J., M. Shtutman, and A. Ben-Ze'ev. 2000. Differential mechanisms of LEF/TCF family-dependent transcriptional activation by beta-catenin and plakoglobin. Mol. Cell. Biol. 20:4238–4252.
   PubMed Web of Science ®Google Scholar
• Zhurinsky, J., M. Shtutman, and A. Ben-Ze'ev. 2000. Plakoglobin and β-catenin: protein interactions, regulation and biological roles. J. Cell Sci. 113:3127–3139.
   PubMed Web of Science ®Google Scholar
• Zurawel, R., S. Chiappa, C. Allen, and C. Raffel. 1998. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res. 58:896–899.
   PubMed Web of Science ®Google Scholar